FindTrial
Sign In

A study to compare Biochip and direct immunofluorescence in diagnosis of autoimmune bullous diseases.

Comparative analysis of biochip mosaic based indirect immunofluorescence with direct immunofluorescence in diagnosis of autoimmune bullous skin diseases.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/03/018032
Enrollment
40
Registered
2019-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L123- Acquired epidermolysis bullosa Health Condition 2: L120- Bullous pemphigoid Health Condition 3: L128- Other pemphigoid Health Condition 4: L102- Pemphigus foliaceous Health Condition 5: L100- Pemphigus vulgaris

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

P Arunprasath
Lead Sponsor
Indian Association of Dermatologists Venereologists and Leprologists
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All new cases of autoimmune bullous disease. Autoimmune bullous disease patients under treatment with active disease.

Exclusion criteria

Exclusion criteria: Autoimmune bullous disease Patients in clinical remission

Design outcomes

Primary

MeasureTime frame
To find out whether biochip can be used as a routine diagnostic technique in the diagnosis of autoimmune bullous skin diseases by comparing with an already existing gold standard method direct immunofluorescence.Timepoint: 1 year—

Secondary

MeasureTime frame
Autoimmune bullous skin disorders showing floor binding in salt split skin could be further evaluated using target antigen study and further typified into rare pemphigoid variants like Anti-p200 pemphigoid, Laminin 332 pemphigoid.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Reena Rai

PSG Institute of Medical Sciences and Research

drreena_rai@yahoo.co.in9894160713

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026